clinical parameter News
-
Serum 14-3-3? A Predictor Of Secondary Sjögren’s Syndrome In SLE
Do you have a patient with Systemic Lupus Erythematosus (SLE) that you suspect may also have Sjögren’s Syndrome (SS)? With shared clinical and serological features, overlapping SS with SLE is a comorbidity that is often challenging to identify to promptly assist clinical management. This may also lead to misdiagnoses of other connective tissue disorders. New data on 14-3-3η (eta) ...
-
Redox Check-Up
A new Service for the Medical Practice Reactive Oxygen Species (ROS) represent one of the most abundant types of free radicals. In physiological conditions ROS levels are regulated by a fine equilibrium namely RedOx balance. When ROS production outperforms the physiological ability to counteract the deleterious effects of these reactive species a condition known as oxidative stress (OS) ...
By H & D S.r.l.
-
New Oncotype DX Real-World Evidence Shows for the First Time the Practice-Changing Impact of TAILORx Results
Data obtained in real-life setting from more than 800 patients with node-negative or nodepositive early-stage breast cancer highlight the test’s impact on clinical practice with chemotherapy-sparing effect Publication of landmark TAILORx study results led to greater reduction in chemotherapy recommendations Exact Sciences Corp. today announced results from a prospective clinical ...
-
Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 Patients
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies to deliver oxygen to areas of the body where it is needed most, today announced completion and topline data from the open-label, Phase 1b clinical trial of its novel, diffusion-enhancing therapeutic, trans sodium crocetinate ...
By CervoMed
-
New Data Confirms Cardiac Dimensions’ Carillon System Shows Favorable Long-Term Survival Rate in Patients with Functional Mitral Regurgitation
Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure (HF), today announced the findings of a post hoc analysis of pooled prospectively collected data from three studies of the Carillon Mitral Contour System® with a focus on 5-year survival rate and the determinants of long-term ...
-
Evolution of ePROM: Advancements, Concerns, and the Way Forward
Patients’ directly reported outcomes in certain rare and chronic diseases are considered reliable for understanding the disease’s natural history, palliative treatments that focus primarily on symptom control, and quality of life. Electronic Patient-Reported Outcome Measures (ePROMs) are now allowing these patients to self-report health conditions and treatment effectiveness ...
-
BioVentrix Announces Ralph Stephan von Bardeleben, MD, as Co- Principal Investigator of the REVIVE-HF Clinical Trial
BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, today announced that Ralph Stephan von Bardeleben, MD, of the University Medical Center of Mainz (Germany) has joined the European REVIVE-HF clinical trial of the Revivent TC™ Transcatheter Ventricular Enhancement System as co-principal investigator. Dr. von Bardeleben heads ...
-
Emmaus Life Sciences Presented Positive Real-World Data on the Efficacy of Endari in Preventing Acute Complications from Sickle Cell Disease at the 62nd Annual Scientific Meeting of the British Society for Haematology
Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced real-world data on Endari®, the company’s prescription-grade L-glutamine oral powder, in preventing acute complications from sickle cell disease (SCD) and hemolysis in pediatric and adult patients in French Guiana and Qatar. The data ...
-
Fractyl Health Publishes Two-Year Durability Data After a Single Revita DMR Therapeutic Procedure in Patients with Type 2 Diabetes
REVITA-1 was an open-label cohort study evaluating Revita® in patients with type 2 diabetes on oral anti-diabetic agents but not yet on insulin This is the first publication showing two-year durability of improvements in blood glucose, weight, and broader metabolic parameters with no device- or procedure-related adverse events in long-term follow-up after a single Revita procedure ...
-
PixCell Medical Partners with Triolab to Distribute Hematological Analyzer HemoScreen in Sweden
PixCell Medical, innovator of rapid diagnostic solutions at the point-ofcare, today announced a partnership with Triolab, the largest diagnostics distributor in the Nordic and Baltic countries, to be the sole distributor in Sweden of the HemoScreen™, PixCell’s hematology analyzer designed for use at the point of care. “PixCell’s HemoScreen brings lab-quality haematology ...
-
Cleveland Diagnostics Presents New Data Supporting the Clinical Validation and Clinical Utility of IsoPSA at the 2021 Annual Meeting of American Urological Association
Cleveland Diagnostics, Inc., a commercial stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that Eric Klein, MD, Chairman of the Glickman Urological & Kidney Institute at Cleveland Clinic, delivered two presentations at the annual meeting of the American Urological Association regarding the company’s prostate ...
-
PixCell Medical Partners with Axonlab to Distribute Point-of-Care Hematological Analyzer HemoScreen Across Europe
PixCell Medical, innovator of rapid diagnostic solutions at the point-of-care, today announced an exclusive distribution agreement with Axonlab, a leader in point-of-care testing in Europe providing the healthcare sector with equipment and services in the fields of medical diagnostics, life science, and software solutions, to distribute the HemoScreen™, PixCell's hematology analyzer, in key ...
-
Aidian Appointed Sole Distributor of PixCell Medical’s Point-of-Care Hematological Analyzer HemoScreen in the Nordics
PixCell Medical, innovator of rapid diagnostic solutions at the point-ofcare, today announced a partnership with Aidian, a Finland-based in-vitro diagnostics company providing reliable, fast, and easy-to-use diagnostic tests for primary care. Aidian will serve as the sole distributor of PixCell’s HemoScreen™, a hematology analyzer designed for use at the point of care, with exclusive ...
-
PixCell Medical and Gamidor Diagnostics Partner to Introduce Point-of-Care Hematology Analysis in Israelq
PixCell Medical, innovator of rapid diagnostic solutions at the point-of-care, today announced it has signed an exclusive distribution agreement with medical diagnostics company Gamidor Diagnostics to distribute the HemoScreen™, PixCell's hematology analyzer, across Israel. This deal follows a global shift spurred by the COVID-19 pandemic towards near-patient, digitally connected testing ...
-
PixCell Medical Signs Point of Care Diagnostics as Sole Distributor of HemoScreen™ in Australasia Region
PixCell Medical, innovator of rapid diagnostic solutions at the point-of-care, announced today that it has signed a distribution agreement with Point of Care Diagnostics Aus. Pty Ltd (POCD), supplier and distributor of point-of-care testing solutions to Australasia, making POCD the sole regional distributor of the HemoScreen™, a small-sized, simple-to-operate diagnostic platform designed ...
-
Enalare Therapeutics Announces Positive Topline Results With ENA001 in a Propofol Induced Respiratory Depression Study
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has completed a propofol induced respiratory depression study with its lead compound ENA001, having achieved the targeted primary endpoint. The objective of the study was to demonstrate the ability of ENA001 ...
-
BrainScope Receives FDA Clearance for Multi-Modal, Multi-Parameter Concussion Assessment
BrainScope®, a medical neuro-technology company focused on concussion and mild traumatic brain injury (mTBI) assessment, announced today that it has received FDA clearance to include additional language in its product’s Indications for Use (IFU), adding key terminology related to “multi-modal, multi-parameter assessment" of “concussion" and “mild Traumatic Brain ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you